Disease Focus

We are focused on the development of a next-generation drug to benefit the millions of people suffering from dry eye disease and other inflammatory diseases of the eye. Our immediate goal is to overcome the limitations of current dry eye treatments with the development of a first-in-class drug that combines both anti-inflammatory and pain reducing activity.